History

Company.

History

2022

06
Residual CHO gDNA Analysis Product Launched
2021

07
Launched RCL analysis product jointly developed with
Seoul National University Hospital
2020

12
Obtained CE Mark certification

09
COVID-19 RT-qLAMP PCR Diagnostic Kit Export Licensed

07
R&D Partnership Agreement with Seoul National University Hospital's Advanced Cell and Gene Therapy Center

06
Got permission to manufacture in vitro diagnostic medical devices
2019

03
Obtained ISO13485 certification
2018

06

Launched in Germany (PELOBIOTECH GmbH)

Launched in Singapore (Afirmus Biosource Pte. Ltd.)

Expanded the GMP-grade plant

04
Launched in Taiwan (Tseng Hsiang Life Science Ltd.)

03
Established a branch office in Singapore (Spectrum incubating, Golden Equator)
2017

04
Launched in Japan (Primetech)

02
Established a GMP-grade manufacturing plant
2016

12
Won the prime minister’s citation

05
"Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells" (patent registered, Korea)
2015

10
“Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (patent registered, Japan)
2014

08
"Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells" (2 patents registered, USA)
2013

08
“Method for eliminating mycoplasma contamination of cells”
(Patent registered, Korea)
2012

08
Launched a diagnosis kit for the Mycoplasma qPCR

04
Acknowledged company-affiliated research institute
(Korea Industrial Technology Association)
2011

08
Launched the mycoplasma-related products in the United States
2010

10
“Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (Patent registered, Korea)

02
Certified as a venture company (Korea Technology Finance Corporation)
2009

10
Selected for residence in the business incubation center
of Ajou University and started the business